Testing Pain Relief in Cancer: Methadone plus Morphine vs. Morphine Alone
Phase 3
- Conditions
- Health Condition 1: R52- Pain, unspecified
- Registration Number
- CTRI/2023/11/059946
- Lead Sponsor
- Dr Noor Husain
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patients with cancer pain (any cancer) requiring opioid(morphine) for analgesia
Exclusion Criteria
1)Cognitive impairment
2)Patients already on any opioid
3)Psychiatric disease
4)Illicit drug users
5)Hypersensitivity or allergy to study drugs
6)Pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of incidence of opioid related adverse events between both groups.Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1)Mean daily pain free period <br/ ><br>2)Mean dose of morphine <br/ ><br>3)Measure of pain intensity on numerical rating scale <br/ ><br>4) Measure of mean daily laxative dose <br/ ><br>5)Cost effectiveness ratio of both groupsTimepoint: 6 months